AGÕæÈ˹ٷ½

Freshworks Inc. (FRSH) â€� Form 4 insider transaction filed 07/02/2025

Director Francis J. Pelzer reported the annual equity retainer granted under the company’s Non-Employee Director Compensation Policy. The award consists of 13,236 Restricted Stock Units (RSUs), each convertible into one share of Class A common stock upon settlement. The grant date is 07/01/2025 and the RSUs vest in full on 07/01/2026, subject to accelerated vesting should the director fail to be re-elected at the next annual meeting.

No shares were sold or otherwise disposed of; the aggregate beneficial ownership for Mr. Pelzer following the award is 43,374 Class A shares, all held directly. The transaction price is recorded as $0, reflecting the compensatory nature of the RSU grant rather than an open-market purchase.

This filing represents routine board compensation and does not alter the company’s capital structure or signal a strategic shift. Investors typically view such grants as neutral from a valuation standpoint, although continued equity awards do incrementally align director interests with shareholder value.

Freshworks Inc. (FRSH) filed a Form 4 disclosing that non-employee director Randy Gottfried received an annual equity grant of 13,236 Class A RSUs on 01-Jul-2025. The award, made under the company’s Non-Employee Director Compensation Policy, carries an exercise/price of $0 and converts 1-for-1 into common shares. The RSUs vest in full on 01-Jul-2026, or earlier should the director fail to be re-elected at the next annual meeting. After the grant Mr. Gottfried’s direct beneficial ownership rises to 53,920 shares. No derivative security transactions were reported. The filing is routine, reflects standard board compensation and results in de-minimis dilution relative to FRSH’s ~300 million shares outstanding.

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).

The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.

Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.

Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA â€� FURMO-006) is scheduled to begin 2H 2025.

Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.

Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.

Timeline: closing and delivery are expected on or about 3 July 2025.

Centene Corporation (CNC) Form 4 filing: Director Frederick H. Eppinger reported the acquisition of 463 shares of common stock on 06/30/2025 at a stated price of $0.00, indicating an equity award rather than an open-market purchase. Following the transaction, Eppinger directly owns 359,042.658 shares, which includes 5,965 restricted stock units (RSUs) subject to future vesting. No derivative securities transactions were reported. The filing was signed by attorney-in-fact Christopher A. Koster on 07/02/2025.

The transaction modestly increases the director’s stake by approximately 0.13%, providing incremental alignment with shareholder interests but does not represent a market-based purchase. No other insider transactions or material events were disclosed in this short-form filing.

GitLab Inc. (NASDAQ: GTLB) has filed a Form 144 disclosing the proposed sale of 1,214 shares of its Class A common stock under Rule 144. The shares, valued at roughly $55,249, account for less than 0.001 % of the company’s approximately 146.1 million shares outstanding, making the transaction immaterial to GitLab’s overall float and market liquidity.

The seller acquired the stock as restricted stock units (RSUs) on 27 June 2025 and intends to execute the sale through Morgan Stanley Smith Barney LLC on or after 2 July 2025. No additional sales by this filer have occurred in the past three months. The notice states that the filer is unaware of any non-public adverse information, suggesting this is a routine liquidity event rather than a signal of strategic change.

-

Everi Holdings Inc. (EVRI) filed Post-Effective Amendment No. 1 to twelve prior Form S-8 registration statements covering an aggregate of approximately 48.6 million shares of common stock reserved for various equity compensation plans dating back to 2006. The amendment formally deregisters all unsold shares under those statements.

The action follows the 1 July 2025 closing of a multi-party transaction in which funds managed by affiliates of Apollo Global Management (through Voyager Parent, LLC) simultaneously acquired Everi and International Game Technology PLC’s Gaming & Digital business:

• IGT transferred its Gaming & Digital assets to Ignite Rotate LLC ("Spinco") and related liabilities (the “Separationâ€�).
• Buyer purchased all Spinco units and IGT Canada Solutions ULC shares.
• Voyager Merger Sub, Inc. merged with and into Everi, making Everi a wholly owned subsidiary of Buyer (the “Mergerâ€�).

Because Everi’s common stock will be delisted and deregistered under Section 12(b) of the Exchange Act, the company is terminating all outstanding securities offerings. Upon effectiveness of this filing, no shares remain registered for sale under the referenced S-8 statements.

Geron Corporation (ticker GERN) has filed a Form S-8 to register an additional 26 million shares of common stock for employee benefit purposes:

• 20 million shares for the 2018 Equity Incentive Plan
• 6 million shares for the 2014 Employee Stock Purchase Plan (ESPP)

The filing relies on General Instruction E, incorporating prior S-8 registrations and other Exchange Act reports by reference. No new financial statements are presented; the document is strictly a securities registration to expand share capacity under existing compensation plans. The company remains a large accelerated filer and confirms it meets all Form S-8 eligibility requirements. Key exhibits include updated plan documents (Exhibits 99.1 & 99.2), legal opinions, and auditor consent.

For investors, the filing signals continued use of equity-based compensation, which can motivate employees but may incrementally dilute existing shareholders as the newly registered shares are issued over time.